Engages in the discovery, development and commercialization of new therapies
Cardiome Pharma Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of new therapies that will improve the health of patients around the world.
Its product BrinavessTM approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.
Cardiome Pharma was founded on December 12, 1986 and is headquartered in Vancouver, Canada.
Number of employees : 75 persons.
|CAD (in Million)||%||CAD (in Million)||%|
|Pharmaceutical Product Development||0.789||100%||4.65||100%|| +83.03%|
|CAD (in Million)||%|
|Rest of the World||2.69||57.9%|
|Fidelity Management & Research Co. ||1,595,312||
|FIG LLC (Private Equity) ||981,596||
|Adage Capital Management LP ||950,000||
|Putnam Investment Management LLC ||923,281||
|Westfield Capital Management Co. LP ||730,926||
|William L. Hunter, MD ||510,000||
|Clough Capital Partners LP ||499,004||
|AlphaOne Investment Services LLC ||198,157||
|Turner Investments LP ||143,303||
|Renaissance Technologies LLC ||84,113||
|Company contact information|
|Cardiome Pharma Corp.|
6190 Agronomy Road
Vancouver, BC V6T 1Z3
Phone : +1.604.677.6905
Fax : +1.604.677.6915
Web : www.cardiome.com
© 2015 Factset